Psilocybin and dementia: systemic barriers to psychedelic therapy research amid colonial drug policies and profit-driven healthcare
Original framing: “Magic mushrooms and Alzheimer’s: what one remarkable case can tell us” — The Conversation - Global
The trickster here is the psilocybin molecule itself—a humble mushroom that upends the entire edifice of Western pharmacology, which demands patentable, single-molecule solutions to complex human suffering. Like Hermes, it slips through the cracks of regulatory frameworks, offering healing where pharmaceutical capitalism has failed, yet its power is trivialized as 'anecdotal' while opioids and benzodiazepines flood the market. The irony is that a substance used for centuries by Indigenous healers is now being 'discovered' by the same institutions that criminalized its use, all while framing it as a 'breakthrough' rather than a return to ancient wisdom.
The 'remarkable case' of psilocybin and dementia is not an isolated miracle but a symptom of deeper systemic failures: the criminalization of Indigenous healing practices, the underfunding of dementia research, and the extractive logic of Western biomedicine.
The Mazatec tradition, which has used teonanácatl for centuries, offers a holistic framework where healing is communal and spiritual, contrasting with the reductionist, profit-driven approach of modern pharmacology. The suppression of psychedelic research during the War on Drugs era—rooted in political repression—mirrors earlier colonial patterns of erasing Indigenous knowledge to impose Western medical systems. Yet the psilocybin molecule, like the trickster Hermes, slips through these cracks, offering a path forward that requires not just scientific rigor but cultural humility and policy reform. The solution lies in decolonizing research, decriminalizing psychedelics, and centering marginalized voices in both science and care, ensuring that future breakthroughs are accessible, equitable, and rooted in ancient wisdom rather than corporate exploitation.